Correcting Hypocapnia in Aneurysmal Subarachnoid Hemorrhage.
China80 participantsStarted 2026-01-01
Plain-language summary
Based on the clinical observation that over half of the patients in the management of aneurysmal subarachnoid hemorrhage(aSAH) present with spontaneous hyperventilation, which is significantly associated with delayed cerebral ischemia and poor neurological outcomes, this prospective pilot study is designed to investigate the safety and efficacy of normobaric facemask oxygen for hypocapnia in aSAH.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age \> 18 years.
. Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH), with the presence of an aneurysm verified by computed tomography (CT), CT angiography (CTA), or digital subtraction angiography (DSA).
. Hunt-Hess grade II-IV.
. Presence of hypocapnia on arterial blood gas analysis, defined as PaCO2 \< 35 mmH;
. PaO2 \> 90 mmHg.
Exclusion criteria
. Presence of brain herniation or refractory intracranial hypertension, defined as a baseline intracranial pressure (ICP) \> 25 mmHg that responds poorly to conventional ICP-lowering therapy;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
modified Rankin Scale (mRS) >3
Timeframe: 90-day follow-up visit
2
Incidence of delayed cerebral injury (DCI)
Timeframe: 30 days after onset
Trial details
NCT IDNCT07343232
SponsorThe Chinese University of Hong Kong, Shenzhen
. Primary respiratory diseases (e.g., chronic obstructive pulmonary disease, severe asthma) known to cause chronically elevated baseline PaCO2;
. Severe acid-base disturbances other than respiratory alkalosis.
. Severe cardiac insufficiency, severe hepatic or renal dysfunction, malignant tumors, or other severe comorbidities that significantly impact prognosis;
. Before the onset of the disease, the mRS score was greater than 2, and there were other factors causing disability.
. Life expectancy \< 3 months;
. Any other condition deemed by the investigator to pose a high risk warranting exclusion.